Literature DB >> 2437953

Fertility after chemotherapy for ovarian germ cell tumours.

D Pektasides, G J Rustin, E S Newlands, R H Begent, K D Bagshawe.   

Abstract

Gonadal function was assessed in 17 women who successfully completed chemotherapy with the POMB/ACE regimen (cisplatin, vincristine [Oncovin], methotrexate, bleomycin/actinomycin D, cyclophosphamide, etoposide) for ovarian germ cell tumours, and had a remaining ovary and uterus. A 20-year-old girl has not yet recovered menstruation 5 months off chemotherapy. All the remaining women whose mean age at start of chemotherapy was 21 (9-38) are now menstruating with a median time of recovery of 41/2 months after completion of chemotherapy. Five women have so far conceived after chemotherapy resulting in three full term normal deliveries of healthy infants, one termination of pregnancy, two miscarriages and one continuing pregnancy. Gonadal function does not appear to be permanently impaired in the majority of patients receiving POMB/ACE chemotherapy for ovarian germ cell tumours.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437953     DOI: 10.1111/j.1471-0528.1987.tb03129.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  3 in total

1.  Managing malignant ovarian germ cell tumours.

Authors:  G J Rustin
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-10

2.  Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012.

Authors:  Soledad Jorge; Nathaniel L Jones; Ling Chen; June Y Hou; Ana I Tergas; William M Burke; Cande V Ananth; Alfred I Neugut; Dawn L Herhshman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2016-06-01       Impact factor: 5.482

3.  Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.

Authors:  J Gaffan; L Holden; E S Newlands; D Short; S Fuller; R H J Begent; G J S Rustin; M J Seckl
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.